REG - Hemogenyx Pharma Plc - Placing to raise £340,000

Hemogenyx PharmaceuticalsAnnouncement

08/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250108:nRSH4861Sa&default-theme=true

RNS Number : 4861S  Hemogenyx Pharmaceuticals PLC  08 January 2025

8 January 2025

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Placing to raise £340,000

 

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that it has
raised £340,000 through the issue of 100,000 new ordinary shares ("Placing
Shares") at a price of 340p per share (the "Placing"). One institutional
investor has subscribed for the Placing Shares and has also been granted
50,000 warrants exercisable at a price of 500p each for a period of 12 months
from 1 March 2025.

 

The Placing uses the Company's current headroom to issue ordinary shares for
cash. The net proceeds of the Placing will be dedicated to the clinical trial
of the Company's lead asset, HG-CT-1, targeting relapsed/refractory (R/R)
acute myeloid leukemia (AML) in adults. The first patient for the trial is
recruited and being tested for inclusion/exclusion criteria to satisfy the
clinical protocol. The funds raised will also assist the Company into the next
stage of the trials.

 

An application is being made to the Main Market of the London Stock Exchange,
and admission of the Placing Shares to trading is expected on or around 15
January 2025 ("Admission"). The Placing Shares will rank pari passu with the
Company's existing Ordinary Shares.

 

 

Total Voting Rights

 

For the purpose of the Disclosure Guidance and Transparency Rules, following
Admission the enlarged issued share capital of the Company will comprise
3,604,539 ordinary shares. The Company does not hold any shares in treasury.
The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company, under the
Disclosure Guidance and Transparency Rules.

 

Market Abuse Regulation (MAR) Disclosure

 

Certain information contained in this announcement would have been inside
information for the purposes of Article 7 of Regulation No 596/2014 (as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement. The person responsible for
arranging for the release of this announcement on behalf of Hemogenyx
Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer &
Co-Founder.

 

 

 

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)

 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl

 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

The Company is a clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune disease and to bring
the curative power of bone marrow transplantation to a greater number of
patients suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and complementary
product candidates, as well as a platform technology that it uses as an engine
for novel product development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOELDLLBEFLBBBB